Why taking the trip out of psychedelic medicine is a mistake

A 2022 article in Nature proclaimed the possibility of “Taking the tripping out of psychedelic medicine,” highlighting efforts to engineer medically-compliant designer psychedelics purportedly delivering mental health benefits without inducing subjective experiences. Such developments have since initiated a new mainstream in the pharmaceuticalization and commodification of psychedelics. These so-called ‘psychoplastogens’ streamline drugs to maximize scalability, standardization, and compatibility with medical and economic infrastructures. Yet stripping psychedelics of their phenomenological core, risks eliminating their most transformative therapeutic and societal effects. Drawing on ‘ecodelics,’ i.e., psychedelics understood as agents of relational and ecological attunement, we assess biochemical reductionist framings of psychedelic medicine, foregrounding the crucial role of set, setting, and social context (matrix). The pharmaceuticalization of psychedelics risks narrowing these substances to individualized biochemical interventions, sidelining the relational, ecological, and transformative dimensions through which they exert their broader therapeutic and societal benefits. Psychedelics’ capacity to foster connectedness – to self, community, and nature – cannot be engineered out without consequence. We argue that the pharmaceutical turn in psychedelic science, while motivated by scalability and safety (and profit), indicates a deeper category error: treating subjective experience as pathological noise rather than as the principal mechanism of action. We argue for reintegrating psychedelics into relational, communal, and ecologically attuned practices, recognizing psychedelics not merely as isolated pharmacological agents but as non-specific amplifiers of experience dependent on social and ecological reinforcing scaffolding. If psychedelics are co-opted to sustain unsustainable systems, their emancipatory potential risks being lost at a moment when it is most urgently needed.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Policy
Published
2026-09-09
DOI
https://doi.org/10.1016/j.drugpo.2026.105487
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Why taking the trip out of psychedelic medicine is a mistake

Yogi Hale Hendlin, Julian Heller
International Journal of Drug Policy
Psychedelics and Drug Studies
article

Why taking the trip out of psychedelic medicine is a mistake

Yogi Hale Hendlin, Julian Heller
article en

Abstract

A 2022 article in Nature proclaimed the possibility of “Taking the tripping out of psychedelic medicine,” highlighting efforts to engineer medically-compliant designer psychedelics purportedly delivering mental health benefits without inducing subjective experiences. Such developments have since initiated a new mainstream in the pharmaceuticalization and commodification of psychedelics. These so-called ‘psychoplastogens’ streamline drugs to maximize scalability, standardization, and compatibility with medical and economic infrastructures. Yet stripping psychedelics of their phenomenological core, risks eliminating their most transformative therapeutic and societal effects. Drawing on ‘ecodelics,’ i.e., psychedelics understood as agents of relational and ecological attunement, we assess biochemical reductionist framings of psychedelic medicine, foregrounding the crucial role of set, setting, and social context (matrix). The pharmaceuticalization of psychedelics risks narrowing these substances to individualized biochemical interventions, sidelining the relational, ecological, and transformative dimensions through which they exert their broader therapeutic and societal benefits. Psychedelics’ capacity to foster connectedness – to self, community, and nature – cannot be engineered out without consequence. We argue that the pharmaceutical turn in psychedelic science, while motivated by scalability and safety (and profit), indicates a deeper category error: treating subjective experience as pathological noise rather than as the principal mechanism of action. We argue for reintegrating psychedelics into relational, communal, and ecologically attuned practices, recognizing psychedelics not merely as isolated pharmacological agents but as non-specific amplifiers of experience dependent on social and ecological reinforcing scaffolding. If psychedelics are co-opted to sustain unsustainable systems, their emancipatory potential risks being lost at a moment when it is most urgently needed.

International Journal of Drug PolicyVol. 157
Cognitive Research (United States) (US), Erasmus University Rotterdam (NL)
Industry, innovation and infrastructure
Openalex Percentile: Top 7%
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.